Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Top Cited Papers
Open Access
- 7 August 2014
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 168 (5), 682-689.e1
- https://doi.org/10.1016/j.ahj.2014.07.028
Abstract
No abstract availableKeywords
Funding Information
- Sanofi-Aventis SA
- Regeneron Pharmaceuticals
This publication has 26 references indexed in Scilit:
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeThe New England Journal of Medicine, 2012
- Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease PatientsCholesterol, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterolJournal of Lipid Research, 2010
- Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study)European Heart Journal, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusThe New England Journal of Medicine, 2010
- EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countriesEuropean Journal of Preventive Cardiology, 2009
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseThe New England Journal of Medicine, 2006
- Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy: A PROVE IT-TIMI 22 SubstudyJournal of the American College of Cardiology, 2005
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005